テルミサルタンによる心血管疾患予防の臨床試験

基本情報

NCT ID

NCT01075698

ステータス

完了

試験のフェーズ

第4相

試験タイプ

介入

目標被験者数

1,228

治験依頼者名

Kumamoto University

概要

The present research is conducted as a randomized, parallel-group, controlled, open study (using the PROBE method) to primarily verify the effects on various biomarkers in high-risk hypertensive patients treated with ARB (telmisartan, ARB group) as compared with those in patients receiving ordinary therapy (non-ARB group (ordinary therapy group)). In addition, onset of cardiovascular events and levels of markers that are associated with cardiovascular events are observed over time to examine the significance of each marker. The biomarkers will be obtained at the start of the study (at registration), after 6, 12, 24 and 36 months from the start of the study.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)